Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Randomized phase II trial of sulindac for lung cancer chemoprevention.

Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J; Cancer Prevention Network.

Lung Cancer. 2013 Mar;79(3):254-61. doi: 10.1016/j.lungcan.2012.11.011. Epub 2012 Dec 20.

PMID:
23261228
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Feb;4(2):259-69. doi: 10.1158/1940-6207.CAPR-10-0215. Epub 2011 Jan 5.

PMID:
21209397
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia.

Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF.

J Natl Cancer Inst. 2002 Jul 3;94(13):1001-9.

PMID:
12096085
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK.

J Natl Cancer Inst. 2001 Apr 18;93(8):605-18.

PMID:
11309437
[PubMed - indexed for MEDLINE]
Free Article
5.

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F.

Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5.

PMID:
21296449
[PubMed - indexed for MEDLINE]
6.

Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.

Lam S, Xu X, Parker-Klein H, Le Riche JC, Macaulay C, Guillaud M, Coldman A, Gazdar A, Lotan R.

Int J Oncol. 2003 Dec;23(6):1607-13.

PMID:
14612933
[PubMed - indexed for MEDLINE]
7.

A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.

Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE.

Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.

PMID:
19401528
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Biological activity of celecoxib in the bronchial epithelium of current and former smokers.

Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM.

Cancer Prev Res (Phila). 2010 Feb;3(2):148-59. doi: 10.1158/1940-6207.CAPR-09-0233. Epub 2010 Jan 26.

PMID:
20103722
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR.

J Clin Oncol. 2013 Nov 20;31(33):4179-87. doi: 10.1200/JCO.2013.49.2173. Epub 2013 Sep 3.

PMID:
24002495
[PubMed - indexed for MEDLINE]
10.

Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.

Khuri FR.

Clin Lung Cancer. 2003 Sep;5 Suppl 1:S36-40. Review.

PMID:
14641993
[PubMed - indexed for MEDLINE]
11.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G.

Cancer. 2013 Mar 1;119(5):1023-32. doi: 10.1002/cncr.27836. Epub 2012 Oct 12.

PMID:
23065656
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).

Bradley JD, Scott CB, Paris KJ, Demas WF, Machtay M, Komaki R, Movsas B, Rubin P, Sause WT.

Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1173-9.

PMID:
11955727
[PubMed - indexed for MEDLINE]
13.

Lung cancer chemoprevention with celecoxib in former smokers.

Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D.

Cancer Prev Res (Phila). 2011 Jul;4(7):984-93. doi: 10.1158/1940-6207.CAPR-11-0078.

PMID:
21733822
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers.

Khuri FR, Lee JS, Lippman SM, Lee JJ, Kalapurakal S, Yu R, Ro JY, Morice RC, Hong WK, Hittelman WN.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):311-8.

PMID:
11319170
[PubMed - indexed for MEDLINE]
Free Article
15.

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L.

J Thorac Oncol. 2011 Apr;6(4):781-5. doi: 10.1097/JTO.0b013e31820a0ea6.

PMID:
21289522
[PubMed - indexed for MEDLINE]
16.

Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.

Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM.

Gastroenterology. 2005 Sep;129(3):863-73.

PMID:
16143126
[PubMed - indexed for MEDLINE]
17.

Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, BarĂ³n AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR.

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. doi: 10.1158/1940-6207.CAPR-12-0382. Epub 2012 Dec 26.

PMID:
23268837
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL.

Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3.

PMID:
19258540
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.

Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM; Cancer Prevention Network.

J Clin Pharmacol. 2013 Apr;53(4):403-12. doi: 10.1002/jcph.26. Epub 2013 Feb 22.

PMID:
23436338
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.

Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S.

J Natl Cancer Inst. 1996 Nov 6;88(21):1550-9.

PMID:
8901853
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk